Capricor Therapeutics (NASDAQ:CAPR) Shares Gap Up – What’s Next?

Capricor Therapeutics Inc (NASDAQ:CAPR)’s share price gapped up before the market opened on Thursday . The stock had previously closed at $9.64, but opened at $10.20. Capricor Therapeutics shares last traded at $11.03, with a volume of 897,852 shares.

Analysts Set New Price Targets

CAPR has been the topic of several recent research reports. HC Wainwright reiterated a “buy” rating and issued a $77.00 price objective on shares of Capricor Therapeutics in a research report on Monday, March 17th. Cantor Fitzgerald reiterated an “overweight” rating and set a $30.00 price objective on shares of Capricor Therapeutics in a research report on Thursday, March 20th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to data from MarketBeat, Capricor Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $34.50.

Capricor Therapeutics Stock Performance

The company has a market capitalization of $512.22 million, a price-to-earnings ratio of -10.60 and a beta of 4.65. The business’s 50 day moving average price is $12.43 and its two-hundred day moving average price is $15.10.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.15. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. The firm had revenue of $11.13 million during the quarter, compared to analyst estimates of $9.87 million. On average, sell-side analysts expect that Capricor Therapeutics Inc will post -1.21 earnings per share for the current year.

Institutional Investors Weigh In On Capricor Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Summit Investment Advisors Inc. grew its stake in shares of Capricor Therapeutics by 54.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 1,345 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in Capricor Therapeutics by 172.8% during the fourth quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company’s stock worth $64,000 after buying an additional 2,947 shares in the last quarter. Virtus ETF Advisers LLC acquired a new position in Capricor Therapeutics in the fourth quarter worth approximately $68,000. AlphaQuest LLC bought a new position in shares of Capricor Therapeutics in the fourth quarter valued at $78,000. Finally, New York State Common Retirement Fund lifted its position in shares of Capricor Therapeutics by 625.0% during the 4th quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company’s stock valued at $80,000 after acquiring an additional 5,000 shares during the last quarter. 21.68% of the stock is currently owned by institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.